Welcome
Support Centre
01 November 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma
ISRCTN ISRCTN13256080
DOI 10.1186/ISRCTN13256080
ClinicalTrials.gov identifier
EudraCT number
Public title A phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma
Scientific title
Acronym N/A
Serial number at source CSTI571BNL07; METC 03-044
Study hypothesis In the pathogenesis of medullary thyroid carcinoma a mutation of the rearranged during transfection (RET) tyrosine kinase system plays an essential role. In animal models the tyrosine kinase inhibitor imatinib showed tumor regression. So a phase II study in patients with progressive medullary thyroid carcinoma with imatinib may open new treatment possibilities.
Lay summary
Ethics approval Ethics approval received from the local medical ethics committee
Study design Observational phase II study
Countries of recruitment Netherlands
Disease/condition/study domain Medullary thyroid carcinoma
Participants - inclusion criteria 1. Patients over 18 years of age
2. The subject has advanced histologically proven medullary thyroid cancer. Advanced disease is defined as locally recurrent disease or metastatic disease that is not amenable to curative resection. The subject must have measurable disease.
3. The subject has not received anti-tumor radiotherapy or chemotherapy therapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) of the start of imatinib administration
4. The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of zero to two
5. Adequate end organ function, defined as the following:
5.1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
5.2. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2.5 x ULN
5.3. Creatinine less than 1.5 x ULN
5.4. Absolute neutrophil count (ANC) more than 1.5 x 10^9/L
5.5. Platelets more than 100 x 10^9/L
6. Female patients of childbearing potential must have negative pregnancy test within seven days before initiation of study drug dosing. Postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to three months following discontinuation of study drug.
7. Life expectancy of more than three months (in the absence of any intervention)
8. The subject has voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent prior to any study specific procedures
Participants - exclusion criteria 1. The subject is less than five years free of another primary malignancy except:
1.1. If the other primary malignancy is not currently clinically significant nor requiring active intervention, or
1.2. If the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
2. The subject is with known brain metastases
3. The subject has received any other investigational agents within 28 days of first day of study drug dosing
4. The subject has a current history of a class three to four cardiovascular disability status in accordance with the New York Heart Association Functional Classification:
4.1. Class three is defined as marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes fatigue or dyspnea
4.2. Class four is defined as being unable to carry on any physical activity without symptoms and symptoms are present even at rest. Also, if any physical activity is undertaken, symptoms are increased
5. Female patients who are pregnant or breast-feeding
6. Patient has another severe and/or life-threatening medical disease
7. The subject has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis)
8. The subject has a known diagnosis of human immunodeficiency virus (HIV) infection
9. The subject has received chemotherapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry
10. The subject had a major surgery within two weeks prior to study entry
11. The subject uses therapeutic anticoagulation with warfarins. Low-molecular weight heparin (e.g. Fragmin®) or heparin is permitted.
12. The subject with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
Anticipated start date 11/07/2003
Anticipated end date 11/07/2006
Status of trial Completed
Patient information material
Target number of participants 15
Interventions Oral treatment with 600 - 800 mg imatinib daily.
Primary outcome measure(s) The primary objective is to determine the objective response rate (partial and complete responses) in subjects with advanced medullary thyroid carcinoma.
Secondary outcome measure(s) 1. To determine the time to tumour progression
2. To evaluate overall survival
3. To evaluate the safety profile of Glivec® in advanced medullary thyroid carcinoma
Sources of funding Novartis Pharma B.V. (The Netherlands)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17579194
Contact name Dr  B A  Zonnenberg
  Address University Medical Centre Utrecht (UMCU)
Department of Medical Oncology
Heidelberglaan 100
  City/town Utrecht
  Zip/Postcode 3584 CX
  Country Netherlands
  Tel +31 (0)30 250 6308
  Email B.Zonnenberg@umcutrecht.nl
Sponsor University Medical Centre Utrecht (UMCU) (The Netherlands)
  Address P.O. Box 85500
  City/town Utrecht
  Zip/Postcode 3508 GA
  Country Netherlands
  Sponsor website: http://www.umcutrecht.nl/zorg/
Date applied 23/02/2007
Last edited 20/12/2007
Date ISRCTN assigned 23/02/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.